Daniel J. Levitt
Directeur/Membre du Conseil chez The San Francisco SPCA Hospital
Profil
Daniel J.
Levitt is currently the Director at The San Francisco SPCA Hospital.
He previously held positions such as Director-Clinical Oncology & Immunology at Hoffmann-La Roche, Independent Director at Aquinox Pharmaceuticals, President & Head-Research & Development at Protein Design Labs, Chief Operating & Medical Officer at LadRx Corp., Head-Drug Development at Geron Corp., Chief Medical Officer & Head-Regulatory Affairs at Dynavax Technologies Corp., Executive Vice President-Research & Development at Cerimon Pharmaceuticals, COO & Head-Research & Development at Affymax, and Head-Cytokine Development Unit at Sandoz Pharmaceuticals Corp.
Levitt received his undergraduate degree from Brandeis University and his doctorate from Pritzker School of Medicine.
Postes actifs de Daniel J. Levitt
| Sociétés | Poste | Début |
|---|---|---|
The San Francisco SPCA Hospital
 The San Francisco SPCA Hospital Miscellaneous Commercial ServicesCommercial Services The San Francisco SPCA Hospital provides animal welfare and protection programs. It provides care of animals that are homeless, ill or in need of an advocate also work to educate the community, reduce the number of unwanted kittens and puppies through spaying/neutering, and improve the quality of life for animals and their companions. The company was founded on April 18, 1868 and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | 01/01/2007 |
Anciens postes connus de Daniel J. Levitt
| Sociétés | Poste | Fin |
|---|---|---|
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Directeur/Membre du Conseil | 09/08/2019 |
| LADRX CORPORATION | Directeur des opérations | 07/07/2017 |
| SORRENTO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 30/03/2014 |
Cerimon Pharmaceuticals, Inc.
 Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | Directeur Technique/Scientifique/R&D | 01/02/2009 |
| DYNAVAX TECHNOLOGIES CORPORATION | Directeur Technique/Scientifique/R&D | 01/04/2006 |
Formation de Daniel J. Levitt
| Brandeis University | Undergraduate Degree |
| Pritzker School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| LADRX CORPORATION | Health Technology |
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| GERON CORPORATION | Health Technology |
| SORRENTO THERAPEUTICS, INC. | Health Technology |
| AFFYMAX, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Cerimon Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | Health Technology |
Protein Design Labs, Inc.
 Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Health Technology |
| Sandoz Pharmaceuticals Corp. | |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
The San Francisco SPCA Hospital
The San Francisco SPCA Hospital Miscellaneous Commercial ServicesCommercial Services The San Francisco SPCA Hospital provides animal welfare and protection programs. It provides care of animals that are homeless, ill or in need of an advocate also work to educate the community, reduce the number of unwanted kittens and puppies through spaying/neutering, and improve the quality of life for animals and their companions. The company was founded on April 18, 1868 and is headquartered in San Francisco, CA. | Commercial Services |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
